In contrast with most species, including humans, which have monofunctional forms of the folate biosynthetic enzymes TS (thymidylate synthase) and DHFR (dihydrofolate reductase), several pathogenic protozoal parasites, including Cryptosporidium hominis, contain a bifunctional form of the enzymes on a single polypeptide chain having both catalytic activities. The crystal structure of the bifunctional enzyme TS-DHFR C. hominis reveals a dimer with a 'crossover helix', a swap domain between DHFR domains, unique in that this helical region from one monomer makes extensive contacts with the DHFR active site of the other monomer. In the present study, we used site-directed mutagenesis to probe the role of this crossover helix in DHFR catalysis. Mutations were made to the crossover helix: an 'alanineface' enzyme in which the residues on the face of the helix close to the DHFR active site of the other subunit were mutated to alanine, a 'glycine-face' enzyme in which the same residues were mutated to glycine, and an 'all-alanine' helix in which all residues of the helix were mutated to alanine. These mutant enzymes were studied using a rapid transient kinetic approach. The mutations caused a dramatic decrease in the DHFR activity. The DHFR catalytic activity of the alanine-face mutant enzyme was 30 s −1 , the glycine-face mutant enzyme was 17 s −1 , and the all-alanine helix enzyme was 16 s −1 , all substantially impaired from the wild-type DHFR activity of 152 s −1 . It is clear that loss of helix interactions results in a marked decrease in DHFR activity, supporting a role for this swap domain in DHFR catalysis. The crossover helix provides a unique structural feature of C. hominis bifunctional TS-DHFR that could be exploited as a target for species-specific non-active site inhibitors.
INTRODUCTION
Protozoal parasites, such as Cryptosporidium hominis, Leishmania major, Toxoplasma gondii and Plasmodium falciparum, are unusual in that the TS (thymidylate synthase) and DHFR (dihydrofolate reductase) enzymes exist on a single polypeptide chain to form the bifunctional enzyme TS-DHFR (TS-DHFR is a functional designation as dihydrofolate is produced at TS and used at DHFR; the bifunctional enzyme is also referred to as DHFR-TS because the DHFR domain is at the N-terminal portion of the bifunctional enzyme) [1] . These are essential enzymes and have been established as drug targets. TS catalyses the conversion of dUMP (2 -deoxyuridine monophosphate) and CH 2 H 4 folate (methylene tetrahydrofolate) into dTMP (2 -deoxythymidine monophosphate) and H 2 folate (dihydrofolate). DHFR then catalyses the reduction of H 2 folate by NADPH to form H 4 folate (tetrahydrofolate), which is used for one-carbon transfer reactions in many biochemical processes.
After the determination of the crystal structure of C. hominis TS-DHFR, it was suggested that there are two families of bifunctional TS-DHFR: a short-linker family with an N-terminal tail, as in the kinetoplastids, which includes L. major and the trypanosomes; and a long-linker family which contains a donated or crossover helix, as in the apicomplexan family, containing C. hominis, P. falciparum and T. gondii [2] . The short-linker family has a linker length of two residues (L. major) and an N-terminal tail of 22 residues, which stretches from the DHFR domain and wraps around the TS domain. However, in the apicomplexan TS-DHFR enzymes, there is no N-terminal tail in C. hominis and T. gondii and only a five-amino-acid tail in P. falciparum, and the linker region between the TS and DHFR domains is long (89 residues in P. falciparum, 72 residues in T. gondii and 58 residues in C. hominis). This linker region begins in the DHFR domain of one monomer (monomer A), crosses to the other monomer (monomer B), forms the crossover helix that makes extensive contacts with the opposite DHFR domain, then crosses back to monomer A to form the TS domain ( Figure 1 ).
Apart from structural differences, these enzymes also display unique kinetic behaviours in terms of how the DHFR catalytic activity may be modulated. Moreover, each protozoal species exhibits distinct modes of modulation. The catalytic activity of DHFR from L. major and P. falciparum is enhanced upon TS ligand binding, whereas C. hominis DHFR activity is unaffected by the presence of TS ligands at the TS active site (Table 1) [3] [4] [5] . Despite sharing a linker and crossover helix, P. falciparum and C. hominis clearly differ in terms of DHFR kinetics. A closer look at the P. falciparum structure shows that, although the enzyme does form a crossover helix in the same general orientation as C. hominis, it does not contact the DHFR active site of the other monomer; however, the crossover helix in C. hominis DHFR makes extensive contacts with the catalytically important helix B of the DHFR active site. This unique structural characteristic led us to hypothesize that although there is no domain-domain modulation of catalytic activity between the TS and DHFR domains of the same subunit, the crossover helix swap domain may be responsible for modulating catalysis for Abbreviations used: CH 2 H 4 folate, methylene tetrahydrofolate; DHFR, dihydrofolate reductase; dTMP, 2 -deoxythymidine monophosphate; dUMP, 2 -deoxyuridine monophosphate; FRET, fluorescence resonance energy transfer; H 2 folate, dihydrofolate; H 4 folate, tetrahydrofolate; TS, thymidylate synthase; TS-DHFR, bifunctional form of TS and DHFR on a single polypeptide chain having both catalytic activities. 1 To whom correspondence should be addressed (email karen.anderson@yale.edu). Figure 1 Cryptosporidium hominis TS-DHFR structure (PDB ID: 1QZF) (A) Dimer structure of TS-DHFR. The TS and DHFR domains are labelled. Crossover helix and helix B are also labelled in the DHFR domains. The DHFR ligands, NADP + and H 2 folate are shown in stick formation. (B) Close-up of the crossover helix region. Residues on the crossover helix (light grey) are displayed as well as residues on the active-site helix (dark grey). (C) Space-filling representation highlighting the close interactions of the crossover helix (light grey) and helix B (dark grey) residues. DHFR active-site ligands are shown in stick formation.
the C. hominis DHFR. The residues of this 'crossover helix' were mutated in order to determine whether these structural differences might account for some of the mechanistic differences between enzymes from different species.
Cryptosporidiosis, caused by C. hominis infection, is one of the major causative agents of the diarrhoeal diseases in AIDS patients [6] [7] [8] . There have been several outbreaks of C. hominis infections from contaminated water supplies in the past few years that have sickened thousands including an episode in a New York water amusement park [9, 10] . There is currently no effective treatment for this disease, thus there is an urgent need for new drugs. Further understanding of the mechanistic and structural characteristics of the enzyme may reveal key features of catalytic function that could be exploited in the design of potential species-specific inhibitors.
MATERIALS AND METHODS

Chemicals and reagents
All buffers and reagents were of the highest purity. NADPH and dUMP were purchased from Sigma. The concentration of NADPH was determined by using a molar absorption coefficient (ε) of 6220 M −1 · cm −1 at 340 nm. [ 3 H]-labelled H 2 folate and CH 2 H 4 folate were synthesized as previously described using tritiated folic acid as the starting material [11, 12] . [3 ,5 ,7,9- 3 H]-folic acid was purchased from Moravek Biochemicals.
Plasmids and site-directed mutagenesis
Full-length C. hominis TS-DHFR was encoded in the pTrc99A-rHCp (the 'genotype 1' TS-DHFR gene derived from a human parasite clone), kindly provided by Dr Richard G. Nelson (formerly of the Division of Infectious Diseases, University of California, San Francisco, CA, U.S.A.) and Dr Amy C. Anderson (Department of Pharmaceutical Sciences, University of Conneticut, Storrs, CT, U.S.A.). Site-directed mutagenesis was performed using the Stratagene QuikChange ® kit. The mutations for the alanine-face mutant (K194A, D198A, L202A, D205A, I206A and R210A) were all introduced using a single oligonucleotide that encoded the changes. The same residues were mutated to glycine in the glycine-face mutant. In order to form the all-alanine helix mutation, a second round of PCR was used to introduce the remaining alanine mutations at positions 195, 196, 197, 199, 200, 201, 203, 204, 207 and 208 . DNA sequencing confirmed the presence of all of the mutations. CD spectra of wild-type and all three mutant enzymes were globally the same suggesting overall folding of the proteins is maintained; however, because the expected change in the percentage of helical content for the mutant enzymes were all within error of wild-type, we could not determine by CD whether the crossover helix is maintained as a helix. The poly-alanine sequence has a high propensity to form α-helix [13] , and therefore the alanine-face and all-alanine mutant enzymes will presumably retain the α-helical structure. In addition, based on nnPREDICT, secondary structure prediction software, the alanine sequences are predicted to be helical; however, this software would predict the glycine-face enzyme would not maintain the helical structure [14] . Therefore, the glycine-face mutant was made to determine whether simply the presence of a helix, and not specific interactions, is necessary for maximal catalytic activity.
Protein expression and purification
The proteins were overexpressed in BL21 Escherichia coli and purified using previously described methods [5, 15] . The protein was further purified using a PD-10 column from Amersham Biosciences to remove residual H 2 folate. The concentration of purified C. hominis TS-DHFR was determined spectrophotometrically using a molar absorption coefficient of 80 722 M −1 · cm −1 . The DHFR activity was determined by following the decrease in absorbance at 340 nm ( ε = −12.8 mM −1 · cm −1 ) which corresponds to the conversion of NADPH and H 2 folate into NADP + and H 4 folate. The TS activity was determined by following the increase in absorbance at 340 nm ( ε = 6.4 mM −1 · cm −1 ) as the substrates CH 2 H 4 folate and dUMP are converted into H 2 folate and dTMP [16] . Mutant enzymes were purified in a similar manner to wild-type enzymes. [5] . The quenching solution also contained 10 % sodium ascorbate and 200 mM 2-mercaptoethanol to prevent degradation of the products. To confirm complete quenching of the enzymatic reactions, controls in which substrate was added to a premixed solution of enzyme and quench were performed for each experiment, showing stability of the CH 2 H 4 folate. In addition, a control in which enzyme was allowed to react with substrates for 1 min was performed to show complete conversion into products and ensure the stability of the formed H 4 folate. The rate constants were determined by fitting the data to either a single or double exponential equation using Kaleidagraph.
Rapid chemical quench experiments
HPLC analysis
The tritiated products from the rapid chemical quench experiments were analysed using reversed-phase HPLC connected to a radioactivity flow detector as described previously [17] . The isocratic separation was performed using a BDS-Hypersil C 18 reversed-phase column (250 mm × 6.4 mm) (Alltech) with a flow rate of 1 ml/min using 10 % methanol in 180 mM triethylammonium bicarbonate (pH 8.0). The elution times for the products were as follows: 9 min for H 4 folate, 17 min for H 2 folate and 20 min for CH 2 H 4 folate.
Stopped-flow fluorescence experiments
Stopped-flow experiments were performed using a Kintek SF-2001 apparatus (Kintek Instruments). To determine the rate for the DHFR reaction, coenzyme FRET (fluorescence resonance energy transfer) was measured at an excitation of 290 nm with an output filter at 450 nm. The signal measured at 450 nm would decrease as bound NADPH involved in the FRET is converted into NADP + and released from the enzyme. In single turnover experiments, enzyme (50 μM) was incubated with 500 μM NADPH and then mixed with 10 μM H 2 folate. The data was collected over a given time interval using software provided by Kintek. For burst experiments, 7.5 μM enzyme was incubated with 50 μM H 2 folate and then mixed with 500 μM NADPH. In order to determine whether ligands bound at the TS site would result in an activated DHFR rate, as is seen with other TS-DHFR enzymes from other species, DHFR burst experiments were also examined in the presence of TS ligands. For these experiments, enzyme was incubated in the presence of 100 μM FdUMP (5-fluoro-dUMP; a TS inhibitor), 200 μM CH 2 H 4 folate and 1 mM NADPH, and the reaction was initiated by rapidly mixing with 200 μM H 2 folate. The data was collected over a given time range. Runs (4-7) were collected and averaged. The data were fitted to either a single exponential or burst equation to obtain the rate constants.
RESULTS
Expression and steady-state activity of helix mutants
All of the helix mutants were purified using the previously published protocols [5, 15] and all enzymes were ∼ 95 % pure as measured by SDS/PAGE gel electrophoresis. The DHFR steadystate rates were 2.7 + − 0.1 s for wild-type, alanine-face, glycine-face and all-alanine mutant enzymes respectively. All rates were determined using a spectrophotometric assay.
Single turnover of the DHFR reaction
Single turnover experiments were conducted to directly assess the effects of the mutations on the rate of catalysis at the DHFR site. Experiments were performed using stopped-flow fluorescence ( Figure 2 ). Bifunctional TS-DHFR from wild-type or mutant enzymes was pre-incubated with saturating amounts of NADPH and then mixed with limiting amounts of H 2 folate. The alanine-face mutant catalytic rate was 30 + − 1 s −1 , the glycineface catalytic rate was 17 + − 1 s −1 and the all-alanine catalytic rate was 16 + − 1 s −1 , compared with a catalytic rate of 152 + − 7 s −1 for the wild-type enzyme. Similar experiments were performed using rapid chemical quench. Bifunctional TS-DHFR was pre-incubated with a saturating amount of unlabelled NADPH and then rapidly mixed with a limiting amount of radiolabelled H 2 folate. Similar rates were obtained as compared with the stopped-flow results. Both methods confirm a reduced catalytic rate for all mutant enzymes. Doubling the enzyme concentration did not change the catalytic rate, demonstrating that binding was not ratelimiting in these assays.
Pre-steady-state burst experiments of the DHFR reaction
The DHFR reaction was also studied under pre-steady-state burst conditions (the substrate in slight excess over enzyme), using stopped-flow fluorescence. Bifunctional TS-DHFR was incubated with H 2 folate and then mixed with saturating NADPH. A burst was observed for all enzymes (Figure 3 ), suggesting that chemistry is not the rate-limiting step, but rather a later step, perhaps product release, limits the catalytic cycle. DHFR burst reactions were also performed in the presence of TS ligands in order to determine whether the DHFR rate would be activated in the presence of TS ligands. The DHFR rate did not change in the presence of ligands for any of the mutant enzymes, indicating that there is no enhancement in the DHFR catalytic rate even if the TS active site has bound ligands.
Single turnover of the TS-DHFR reaction
The full bifunctional TS-DHFR reaction was examined using rapid chemical quench. Figure 4 . The build-up of H 2 folate in all enzymes is consistent with previously determined characteristics of C. hominis TS-DHFR. The accumulation of H 2 folate was seen to a greater extent in the all-alanine helix than in wild-type or mutant-face enzymes (6.2 μM compared with 4.1 μM for wild-type enzyme) ( Table 2 ). The H 2 folate also persisted for longer times in all of the mutant enzymes than in the wild-type enzyme (Table 2) . Interestingly, the H 2 folate buildup lasted for much longer times (∼ 0.7 s) in the glycine-face enzyme than either of the alanine mutants. The end result, the rate of H 4 folate formation, was decreased in all of the mutants: wild-type, 10.1 + − 0.9 s −1 ; alanine-face mutant, 6.7 + − 0.8 s −1 ; allalanine mutant, 4.0 + − 0.4 s −1 ; and glycine-face mutant, 1.0 + − 0.3 s −1 . The rates of catalysis for the TS reaction were derived from the full TS-DHFR reaction time courses. Rates were determined from CH 2 H 4 folate consumption. The rates for the alanine-face and the all-alanine helix mutant enzymes were not significantly different from that of wild-type (all within an error of 15 s −1 ). However, in the case of the glycine-face enzyme, the rate for the disappearance of CH 2 H 4 folate was much slower than the other enzymes, with a rate of 2.7 + − 0.5 s −1 . 
DISCUSSION
Based on currently known structures and sequence alignments, the crossover helix appears to be present only in TS-DHFR of the apicomplexan family, including C. hominis, P. falciparum and T. gondii [2] . The linker and crossover helix in C. hominis brings the two DHFR domains in much closer proximity than bifunctional TS-DHFR enzymes with very short linker regions, such as L. major. Based on the structural differences between the families, we tested the role of the crossover helix using a site-directed mutagenesis approach. Our kinetic characterization of C. hominis helix mutations has provided new insight into the role of the crossover helix. The alanine-face, glycine-face and all-alanine helix enzymes have lower DHFR catalytic rates than wild-type enzyme, suggesting that the interactions between the crossover helix and the residues of the opposite DHFR domain are important for maximal DHFR catalytic activity. The crossover helix packs against helix B in the opposite DHFR domain. Residues on helix B opposite from the crossover helix form a portion of the DHFR active site and contain many highly conserved residues including Phe 36 , which is universally conserved and a key residue in the catalytic mechanism of DHFR, specifically the conformational change and hydride transfer [18, 19] . Helix B and the crossover helix form at least seven tight interactions, some of which are as follows: Asp . Therefore mutating residues on the crossover helix may cause slight shifts in the helix of the active site. As shown in E. coli, the DHFR domain proceeds through a series of conformational changes along the reaction pathway, some of which are distal to the active site, and it is therefore possible that small perturbations in these conformational changes, caused by mutations altering helix B-crossover helix packing, could affect catalysis [18, 20] . The additional loss in activity for the all-alanine and glycineface mutant enzymes can be explained by the loss of additional interactions. Although they do not involve helix B, several of these interactions are between the two DHFR domains. Residues on an orthogonal face of the crossover helix interact with a β-sheet of the DHFR domain. There are also interactions between the crossover helix and residues located in the flexible tethers of the crossover domain. It is likely that these interactions are necessary for a maximal DHFR catalytic activity, possibly by positioning the crossover helix in an optimal orientation. The returning tether makes several interactions and hydrogen bonds with the TS domain. The loss of these interactions could explain the reduction in TS steady-state activity for the all-alanine mutant enzyme. Cumulatively, these lost interactions result in an additional 2-fold loss in activity compared with the alanine-face mutant enzyme. In fact, initial experiments mutating residues Leu 203 and Phe 207 on the orthogonal face of the crossover helix cause a loss of activity to 30 s −1 . The argument could be made that a stretch of alanine mutations introduced anywhere in the protein could cause this reduction in rate; however, when the analogous mutations are made in the P. falciparum enzyme, there is no reduction in activity [4] . The crossover helix appears to be necessary to retain the productive conformation of the active-site helix and to allow for proper co-ordinated movement, and thus maximal activity. In the alanine-face and all-alanine mutant enzymes, the crossover helix would presumably still be present; however, in the case of the glycine-face mutant, we would predict that the crossover helix is no longer maintained as a helix. The glycine-face enzyme results in a similar DHFR rate to the all-alanine mutant enzyme, but, surprisingly, substantially alters the TS rate. Because the linker, upon returning to its own domain, makes many contacts with the TS domain, this entire region could be disrupted by the lack of a structurally stable helix. Although we do not observe that ligands binding to TS enhance DHFR activity, there may be a reciprocal modulation of TS activity by DHFR mediated through proper positioning of the crossover helix and linker region. Based on the mutant enzymes made in the present study, it appears that the specific interactions of the crossover helix are necessary for a fully active DHFR domain, whereas simply the presence of a stable helix is important for full TS activity.
Interestingly, L. major, which has a very short linker (∼ two amino acids, and therefore no crossover helix), has a very low DHFR activity of 14 s −1 . However, when ligands are bound at the TS site, the DHFR activity is enhanced approx. 10-fold to a rate of 120 s −1 . This enhanced rate is comparable with the activity of C. hominis DHFR. Interestingly, the C. hominis all-alanine mutant enzyme has an activity (16 s −1 ) equivalent to that of L. major in the unliganded, unenhanced state (14 s −1 ). The bifunctional TS-DHFR enzyme from P. falciparum is an interesting combination of C. hominis and L. major both structurally and catalytically. Structurally, P. falciparum has a long linker containing a crossover helix between the TS and DHFR domains (similar to C. hominis), but also has an N-terminal tail similar to L. major. Unlike C. hominis, P. falciparum DHFR activity increases 2-fold when TS ligands are bound, to reach an enhanced activity of 130 s −1 , similar to the inherent rate of C. hominis DHFR. P. falciparum does have a crossover helix; however, upon mutation of the helix face residues to alanine, there is no reduction in DHFR activity in contrast with that observed for C. hominis [4] , as expected since the helix does not contact the DHFR active site, but rather has electrostatic residues which make contacts with several lysine residues scattered throughout the DHFR domain. It appears that the crossover helix plays a different role in P. falciparum than in C. hominis, offering further evidence that these bifunctional enzymes have developed different modes of modulating or enhancing activity. TS-DHFR from T. gondii also shows an enhanced DHFR activity whether or not ligands are bound at TS, similar to C. hominis TS-DHFR. This parasite is also a member of the apicomplexan family; and, therefore has a long linker and crossover helices, based on secondary structure prediction.
Based on the information in the present study, we would predict that the crossover helix in T. gondii is much like C. hominis, and makes extensive contacts with the DHFR active site of the opposite monomer. Crystallography and mutational studies are currently underway to validate this hypothesis.
It appears that for all species studied, there is a maximal DHFR catalytic rate. An optimized DHFR catalytic rate may be essential in order to help the parasites compete for host folates. It is important to note that folate-dependent enzymes are present in much greater concentrations than folates in the cell (making the concentration of free folates in the cell negligible) and therefore these single-enzyme turnover rates are also probably relevant when studying these enzymes [21, 22] . Rather than TS to DHFR modulation of catalytic activity, as seen in L. major or P. falciparum, our results suggest that an optimal rate is affected by a swap domain between subunits. In addition to influencing the DHFR activity of the monomer to which it crosses, another potential role for the crossover helix is to provide a structural motif which is used for interdomain communication, first proposed by O'Neil et al. [2] . The crossover helix is connected to its own domain through two linkers. The subdomains of the DHFR active site (including helix B) move during the catalytic cycle, resulting in as great as a 1 Å (1 Å = 0.1 nm) shift in position at the active site [23] . Because helix B and the crossover helix are so closely associated, movements of helix B during the catalytic cycle may be transferred to the crossover helix and this 'information' can then be relayed to its own active site through the flexible linker. The information may be used to activate or co-ordinate activity with the other DHFR active site. This would be a unique type of domain-domain communication among the characterized bifunctional TS-DHFR enzymes.
The mutational analysis and mechanistic information we have gained in the present study opens an exciting new avenue of investigation that may be exploited for inhibitor design. Ligands targeted to bind near or adjacent to the crossover helix may also interfere with domain-domain communication and thereby inhibit enzyme activity. A unique pocket is formed by the crossover helix and the tethers that can be targeted for non-active site inhibitors using a molecular docking strategy coupled with virtual library screening [24] . A non-active site TS-DHFR inhibitor would be advantageous because this site would be specific for the bifunctional enzyme and therefore not inhibit the monofunctional (host) enzymes. The successful use of non-active site inhibitors as a component of combination therapy is well-established in the treatment of HIV infections [25] . A potential non-active site inhibitor of C. hominis could work in two ways: (i) by interfering directly with the crossover helix and helix B or (ii) by binding to a site adjacent to the crossover helix. These non-active site inhibitors could be used in conjunction with potential C. hominis DHFR active-site inhibitors as combination therapy [26, 27] , theoretically decreasing the onset of resistance mutations. Development of effective species-specific inhibitors for C. hominis is essential as there are currently no effective treatments for cryptosporidiosis. 
